Eczema Trial, Recruiting (NCT06244212)

Eczema Trial, Recruiting NCT06244212 Sponsor: Wake Forest University Health Sciences Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT06244212 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with skin dermatitis (a type of skin inflammation or rash)
You are older than 9 years of age
You are able to come back for a follow-up visit one week after starting the study
You would be a suitable candidate for treatment with a cream/ointment called triamcinolone 0.1%, even if you were not part of this study
You are a child or adult with active dermatitis who receives skin care at Atrium Health Wake Forest Baptist, Department of Dermatology

Who may not be able to join:

You have not been diagnosed with skin dermatitis
You are unable to return for a follow-up appointment after one week
Less than 2% of your body surface area is affected by dermatitis (meaning only a very small area of skin is involved)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Steven R Feldman, MD, PhD, Wake Forest University Health Sciences

Phone: 336.716.2903

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06244212

Sponsor: Wake Forest University Health Sciences

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 336.716.2903

More information: https://clinicaltrials.gov/study/NCT06244212

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with skin dermatitis (a type of skin inflammation or rash)
You are older than 9 years of age
You are able to come back for a follow-up visit one week after starting the study
You would be a suitable candidate for treatment with a cream/ointment called triamcinolone 0.1%, even if you were not part of this study
You are a child or adult with active dermatitis who receives skin care at Atrium Health Wake Forest Baptist, Department of Dermatology

Who may not be able to join:

You have not been diagnosed with skin dermatitis
You are unable to return for a follow-up appointment after one week
Less than 2% of your body surface area is affected by dermatitis (meaning only a very small area of skin is involved)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Wake Forest University Health Sciences

Registry

ClinicalTrials.gov

Start date

19 September 2024

Est. completion

1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Amount of Topical Medication Dispensed - Demonstration Group; Amount of Topical Medication Dispensed - Standard of Care Group; Amount of Topical Medication Dispensed - Mobile Application Group; Number of times of Application - Demonstration Group; Number of times of Application - Standard of Care Group; Number of times of Application - Mobile Application Group; Change in Investigator Global Assessment (IGA) Scores; Change in Percentage of Body Surface Area (BSA) affected; Subject Questionnaire Scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov